Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

BACKGROUND: Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal eff...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Immunother Cancer
मुख्य लेखकों: Liu, Hao, Zhao, Zhen, Zhang, Li, Li, Yuanke, Jain, Akshay, Barve, Ashutosh, Jin, Wei, Liu, Yanli, Fetse, John, Cheng, Kun
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2019
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805442/
https://ncbi.nlm.nih.gov/pubmed/31640814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0705-y
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन